CFTR and cystic fibrosis: Actually, the Food and Drug Administration (FDA) has approved the use of lumacaftor/ivacaftor (Orkambi®) in patients with CF who have two copies of the F508del CFTR mutation and are 2 years and older; in the same way tezacaftor/ivacaftor (Symdeko®) is approved for individuals 6 years and older with two copies of F508del, as well as for individuals who have a single copy of one of 154 specified mutations, regardless of their other mutation [8].